Triumph in Cancer Treatment: Experimental CAR T-Cell Therapy Works

By the Editorial Team · Tuesday, September 22, 2026

Researchers successfully used GPC3-CAR T-cell therapy to completely eliminate a large, treatment-resistant hepatoblastoma tumor in a 3-year-old boy, with no detectable cancer one year after treatment. This breakthrough suggests that CAR T-cell therapy, previously effective mainly against blood cancers, could be a promising option for treating solid tumors in pediatric patients, though further studies are needed to confirm its broader applicability.

An experimental cancer treatment using Chimeric Antigen Receptor (CAR) T-cell therapy has shown a significant breakthrough in treating a form of childhood liver cancer, researchers reported this month. This development marks a notable advancement in applying CAR T-cell therapy, which has previously been more effective against certain blood cancers but less so with solid tumors.

The therapy was administered to a 3-year-old boy diagnosed with hepatoblastoma, a common pediatric liver cancer. The boy’s tumor had grown to approximately 4.4 by 3.8 by 2.8 inches and had resisted multiple rounds of chemotherapy and surgery. Moreover, the cancer had spread from the liver to his lungs and possibly to his bones, complicating treatment efforts.

Following the failure of conventional treatments, medical teams at Texas Children’s Hospital, Baylor College of Medicine, and Seattle Children’s Hospital turned to an experimental approach known as GPC3-CAR T-cell therapy. This treatment involves genetically modifying the patient’s own white blood cells to target and destroy cancer cells expressing the glypican-3 (GPC3) protein, commonly found in hepatoblastoma tumors.

The patient received two doses of the therapy over an eight-week period. Subsequent evaluations revealed complete regression of the cancer, with no detectable disease one year after treatment. The report detailing these findings was published in the New England Journal of Medicine in September 2026.

CAR T-cell therapy has previously demonstrated effectiveness against certain blood cancers such as leukemia and lymphoma. However, its success against solid tumors has been limited, making this case particularly notable. The recent results add to growing evidence that genetically engineered T-cell therapies may hold promise for treating other difficult pediatric cancers, including deadly brain tumors.

While the outcome in this case is encouraging, researchers emphasize that the therapy was applied to a single patient, and further studies are necessary to confirm safety and broader efficacy. Ongoing clinical trials will help determine whether this approach can be replicated in other patients and solid tumor types.

The promising results represent an important step toward expanding the applications of CAR T-cell therapy beyond hematologic cancers to solid tumors, offering hope for improved outcomes in pediatric cancer patients with resistant diseases.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.